Diligence memo · auto-generated · as of July 2, 2026
Elephas Biosciences Corp
Elephas Biosciences Corp looks fair against its niche peers and is at-risk on financing cadence.
Businessfiled
Elephas Biosciences Corp operates in Biotech / Pharma, based in MADISON.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Elephas Biosciences Corp has raised $114M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $51M on 2023-11-30.
Most recent recorded round closed around 2023-11-30.
Valuation (modeled)modeled
Provath models Elephas Biosciences Corp at approximately $561M (range $162M–$924M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.11× the median modeled value of Series C Biotech / Pharma companies in 2022–2024 (8 peers) — value vs value, same stage and era. Within the normal band (111% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 10 months.
Last raise 2.6 yr ago; this sector typically re-raises about every 15 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round stepped up 1.2× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 94% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 91% of those peers.
Closest niche peers: Sherlock Biosciences, Inc., Pacific Biosciences Of California, Inc., Sudo Biosciences, Inc., NOLA PharmaHoldings, LLC, Belenos Biosciences, Inc..
Peoplefiled
8 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.